Practice
Ribavirin in the treatment of SARS: A new trick for an old drug?
Gideon Koren, Susan King, Sandra Knowles and Elizabeth Phillips
CMAJ May 13, 2003 168 (10) 1289-1292;
Gideon Koren
Susan King
Sandra Knowles
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Ribavirin in the treatment of SARS: A new trick for an old drug?
Gideon Koren, Susan King, Sandra Knowles, Elizabeth Phillips
CMAJ May 2003, 168 (10) 1289-1292;
Jump to section
Related Articles
Cited By...
- Ethical issues in Nipah virus control and research: addressing a neglected disease
- Review and methodological analysis of trials currently testing treatment and prevention options for COVID-19 globally
- Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin
- Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
- Severe Acute Respiratory Syndrome in Dialysis Patients
- The Broad Spectrum Antiviral Nucleoside Ribavirin as a Substrate for a Viral RNA Capping Enzyme
- Antiviral treatment of SARS: Can we draw any conclusions?
- Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)
- Clinical course and management of SARS in health care workers in Toronto: a case series
- SARS update
- La lutte pour confiner le SRAS
- SARS: the struggle for containment